Provision of wound filler

Information

  • Patent Grant
  • 9801761
  • Patent Number
    9,801,761
  • Date Filed
    Tuesday, June 2, 2015
    9 years ago
  • Date Issued
    Tuesday, October 31, 2017
    7 years ago
Abstract
A process of manufacturing a wound dressing filler and/or wound dressing.
Description

The present invention relates to a method and apparatus for providing a wound filler at a wound site prior to the application of negative pressure wound therapy. In particular, but not exclusively, the present invention relates to a method of injecting filler material through a pre-arranged drape at a wound site.


Negative pressure wound therapy (NPWT) has become widely used as a treatment mechanism for chronic or acute wounds. The therapy utilises the application of negative pressure to a wound. This causes mechanical contraction of the wound and/or micro-deformation of the wound-bed stimulating increased blood flow in the surrounding tissues and formation of new granulation tissue. Fluid and other deleterious material is removed from the wound. The wound site is also protected from external contaminants. Often the negative pressure is transmitted to and fluid removed from the wound-bed via a porous wound filler.


Known wound fillers are composed of either foam or gauze and both of these options work well in transmitting negative pressure and removing fluid.


Typically foam fillers, which tend to be of an open celled and possibly reticulated nature, are cut to shape and then packed into the wound cavity. Alternatively, if gauze is used then a pad of gauze is formed and then packed into the cavity. The wound and filler is then sealed using a drape and negative pressure applied via tubes connected in some way through the drape to a source of negative pressure such as a vacuum pump. A single or multi-lumen tube can be utilised to connect the wound site to the negative pressure source. Optionally, the tube or tubes can be fixed to the wound site via a coupling, sometimes referred to as a suction head, adhered to the top of the drape. Alternatively, the tube or tubes can themselves be passed under the drape or through the drape.


US2008/0004549 discloses a system for applying negative pressure on a wound which includes a device configured to provide negative pressure, a dressing sealably covering the wound and a spray-in foam located within the wound below the dressing material. Use of the spray-in foam overcomes the problem that a process of applying a dressing is tedious and time consuming. Unfortunately, US2008/0004549 does not suggest any material which would be suitable as a spray-in foam. Neither does the disclosure teach how the spray-in foam could, in practice, be applied at a wound site. In this sense the patent application is silent as to the necessary details which would enable a skilled person to use spray-in foam as suggested.


The technique suggested in US2008/0004549 is also prone to a problem caused as the foam is sprayed into a wound site. That is to say the foam rises up uncontrollably and would tend to spread too far vertically as well as over the peri-wound area. As such, the foam would require removing from around the wound to prevent skin maceration. Cutting or trimming wound fillers presents a risk to the clinician of leaving behind wound filler in a patient. This could hinder healing and may cause a rejection reaction from the patient's body a future date.


By adhering the drape securely to the peri-wound area (the healthy skin/dermis surrounding the wound), injected foam is prevented or substantially prevented from making contact with the healthy skin/dermal surface. It is well known to those in the art that wound exudate should be prevented, or at least try to prevent as much as possible from making contact with healthy skin/dermis.


For wounds that occur on awkward areas of the body, the packing of the wound can be problematical regardless of the prior known filling technique which is utilised. For example, if the wound is on the side or underside of a body then the filler can easily fall out before a clinician has an opportunity to apply the drape over the filler. Alternatively, the patient may be required to adopt an uncomfortable position in order to prevent the filler from falling out of the wound site. Even the spray in foam technique suggested in US2008/0004549 is prone to such a problem.


It is an aim of the present invention to at least partly mitigate the above-mentioned problems.


It is an aim of certain embodiments of the present invention to provide a method of dressing a wound prior to the application of negative pressure wound therapy in a prompt and efficient manner.


It is an aim of certain embodiments of the present invention to provide a method and apparatus for dressing a wound and a method of applying negative pressure at a wound site in which filler material is not prone to falling out of a wound or being partially dislodged from the wound.


It is an aim of certain embodiments of the present invention to provide a method of dressing a wound which can be applied to awkward areas of the body.


It is an aim of certain embodiments of the present invention to manufacture an improved wound dressing filler and/or wound dressing, having a filler.


The drape of the invention may be any known suitable medical drape in particular it may be a gas permeable or semi-permeable drape coated in a pressure sensitive adhesive, for example Opsite or Tegaderm or other well known drapes in the medical field. Suitably the drape will be a flexible drape. A flexible drape has the advantage of conforming to the treatment area. Also when injecting foam filler into an area enclosed, whether enclosed entirely substantially or partially, having a flexible drape helps ensure a smooth surface, but importantly minimises voids of no foam filler in the area under the drape. This is particularly important when the dressing is being used for negative pressure treatment.


This is also particularly important when the foam is only mixed immediately prior to injection as the foam may still be mixing and reacting to its final composition.


According to a first aspect of the present invention there is provided a method of providing a wound filler at a wound site prior to application of negative pressure wound therapy, the method comprising: securing at least one drape element over a wound site; and subsequently injecting filler material through at least one opening in the drape.


According to a second aspect of the present invention there is provided a method of providing negative pressure wound therapy at a wound site, comprising: securing at least one drape element over a wound site; subsequently injecting filler material through at least one opening in the drape element; connecting the injected filler material to a source of negative pressure; and applying negative to the wound site pressure via said source.


According to a third aspect of the present invention there is provided a method of providing wound filler at a wound site, comprising: providing a wound cavity by covering a wound bed; and subsequently injecting filler material into the wound cavity.


According to some aspects of the present invention there is provided a process of manufacture of a wound dressing filler and/or wound dressing, the process comprising securing at least one drape element over a chosen site; and subsequently injecting wound dressing filler material through at least one opening in the drape.


Further this may be an in situ wound dressing and manufacture thereof. Certain embodiments of the present invention provide the advantage that a wound site is covered with a drape prior to the introduction of filler material. By covering a wound site with a drape a wound chamber region is generated which can then subsequently be filled with an injected material. This has the advantage that wound filler will conform intimately to a wound bed and also be prevented from falling out of a wound. The injected material can be any suitable material such as an injectable foam or string or the like. By the term “the cavity under the drape element” this also includes any cavity partially or substantially enclosed by the drape element not just strictly under.


Certain embodiments of the present invention provide an advantage that a wound chamber defined by a wound bed or wound contact layer and an overlying drape or other type of cover can be filled entirely with filler material. This has the advantage that the drape may fit and secure better at its chosen site as the entire cavity is filled with filler. This may obtain therefore a smooth surface; important for patient comfort should the patient lie on the dressing. This enhances the application of negative pressure across the whole wound bed as well as allowing fluid to be removed from all areas of the wound as there are no voids and/or less wrinkles in the drape.





Embodiments of the present invention will now be described hereinafter, by way of example only, with reference to the accompanying drawings in which:



FIG. 1 illustrates the application of negative pressure wound therapy;



FIG. 2 illustrates covering a wound site with a drape;



FIG. 3 illustrates injecting filler through an aperture in a drape;



FIG. 4 illustrates removal of excess filler; and



FIG. 5 illustrates injecting string like filler material.





In the description like reference numerals refer to like parts.



FIG. 1 illustrates a system (100) for applying negative pressure wound therapy (NPWT) at a wound site (101). The wound site is a region including a wound bed and surrounding skin. As illustrated in FIG. 1, the wound bed (102) is separated in a spaced apart manner from an overlying drape (103) by filler material (104). The drape (103) has an adhesive on a lower surface which enables the drape to be secured around the wound. Other ways of securing a cover over a wound bed are of course possible. An aperture (105) is formed in the drape and a suction head (106) is secured over the aperture. The suction head (106) includes a flange (107) which encircles the aperture (105) and a spout (108) which is secured to a suction tube (109) leading to a vacuum pump system (110).


Alternative forms of negative pressure sources may be utilised according to certain embodiments of the present invention. For example, but not limited to, fixed displacement pumps, syringes, wall suction apparatus, mechanical pumps or the like.


Negative pressure generally refers to pressure less than ambient pressure at a wound site where treatment is to be carried out. Aptly the negative pressure is in the range −10 mmHg to −400 mmHg. Aptly the negative pressure applied is in the range −80 mmHg to −180 mmHg. Aptly the negative pressure applied is I the range −110 mmHg to −140 mmHg.


It will be appreciated that instead of a single suction tube (109) the pumping system (110) may be connected to the suction head (106) via a multi-lumen tube. Also the connecting tube (109) may be itself be formed as multiple tubes which might, from time to time, be connected and reconnected by some sort of coupling device to assist clinical staff.


Although not shown, the pumping system (110) will include a pump enabled to establish suitable ranges of negative pressure either continuously or intermittently and a collecting container such as a canister or bag or the like. One or more filters may be included to prevent contamination of the pumping unit when a disposable container is utilised or to help prevent odours escaping.



FIG. 2 illustrates a wound cavity (200) formed between an upper surface of the wound bed (102) or overlying wound contact layer (not shown) and a lower surface of the drape (103). The wound site corresponds to a region of bodily tissue of any human, animal or other organism. This includes, but is not limited to, bone tissue, dermal tissue, connective tissue or the like. The wound site may include a wound, or defective tissue and/or healthy tissue.



FIG. 2 illustrates an early stage in the application of negative pressure wound therapy at a wound site. A wound and surrounding peri-wound area are prepared and then a drape is secured over the wound bed. Because there is no filler material which can fall out of a wound, healthcare providers have an excellent opportunity to provide a good seal by carefully securing the drape around the wound to ensure a good seal is generated. A hole is then made in the drape by the healthcare provider. Alternatively, a hole may be made in the drape at any point before application to the wound.


An in-situ forming wound filler is applied to the wound site after the drape has been attached to the patient. It has been found that, for example, a liquid foam forming material can be injected through an aperture in the drape to form the filler in the wound chamber. Suitable injectors could be any suitable injector known in the art, these include but not limited to, syringes, double barrel syringes, aerosols, injection guns, dynamic mixers, power mixers and or static mixers 2 or more part static mixers. Suitably a 2 part static mixer could be used for the present invention.


As such, the filler will conform intimately to the wound bed and also be prevented from falling out of the wound by the pre-arranged drape. This enables wounds to be dressed for NPWT on all parts of a body single-handedly or without the need for many assistants without placing a patient in an awkward position. It is advantageous when applying the filler to wounds, for example, on a side of a body, that an aperture in the drape is placed towards the top of the drape in order to allow the injected filler material to fill the cavity from the bottom up.


It will be appreciated that optionally a wound liner can be placed in the wound prior to application of the drape and subsequent in situ forming filler. This may have the advantage of preventing skin formation at the base of the filler material in use.


There are many different materials which are capable of forming a porous structure from liquid starting components. For example, suitable materials are those based on two-part polyurethane chemistry and are formed by mixing an isocyanate pre-polymer with a water/surfactant phase. The isocyanate reacts with the water to cross-link the pre-polymer and at the same time liberate carbon dioxide to produce a porous structure.


Advantageously, formulations are used which cure in less than five minutes. Silicon-based foams are also suitable for use with the present invention. Such materials are two-component liquid systems capable for forming a porous structure. An example is Cavi-care™. Cavi-care™ is a two-part room-temperature vulcanising foam, produced from a polydimethylsiloxane base, a platinum catalyst and hydrogen gas-releasing agent which react together to form a soft-pliable, slightly absorbent white foam. Such material typically cures in around two minutes.


Use of hydrogen as a blowing agent i.e. using a hydrogen gas releasing agent, is advantageous as the small molecule size of hydrogen allows for rapid diffusion through a gas permeable or semi-permeable drape.


Suitably the present invention would be with a solventless system for forming the porous structure for the area under the drape. This could be for instance a 2 part solventless system to produce a porous foam filler in the area under the drape. Rapid gas release through the drape allows for a uniform density, highly porous foam to be generated under the drape. In this way foams of uniform pore size are produced in the enclosure under the drape.


An advantage of the present invention is that the porous structure under the drape is produced in situ. The liquid components are reacting or foaming under the drape to produce the finished dressing and/or dressing filler.


This has many advantages including ensuring an intimate contact with the wound surface.


One advantage that is special to the present invention is the use of a solventless system to produce the porous filler to be situated under the drape.


Certain embodiments of the present invention are directed to the use of solventless systems to produce the porous filler. Such foaming systems only produce gas as a by product when reacting/foaming to produce the final solid/semi-solid product as a filler e.g. foam.


The advantage of having only a gas e.g. Hydrogen as a by product to the reaction, under the drape, to produce the filler of the dressing is that this quickly escapes the dressing through the drape or the edges of the drape to skin contact or indeed the orifice in which the filler was injected. Further it will be appreciated that solvents require heat to change phase from liquid to gas and this heat must be taken from the foam and its surrounding atmosphere, which may include the wound itself. Cooling of a wound may delay healing and cause discomfort to the patient therefore it is to be avoided. Therefore, a further advantage of solventless systems is that there is no endothermic effect on the wound.


Use of solvent based systems to produce the final solid/semi-solid filler under the drape may have the disadvantage of getting rid of the solvent from under the drape and indeed the solvent may be harmful to a patient.


As mentioned above a solventless system in which the filler is produced under the drape in situ, i.e. where the filler is still reacting under the drape to produce its final form has the advantage among other things to enable a good intimate contact with the wound surface.


This intimate contact with the wound surface free of large voids etc is important when the dressing is intended to be used with negative pressure wound therapy.


Aptly the present invention uses a 2 component liquid solventless system to react under the drape to produce a solid porous filler, for example a porous foam filler.


Still this may be silicon based or a polyurethane based for example, porous fillers or porous foam fillers.


Producing only gas as a reacting by product under the drape when producing the final solid/semi solid filler allows a wider range of drapes to be used.


The in-situ forming components of Cavi-care™ can be packaged in a double-barrel syringe (301) of the type illustrated in FIG. 3 which is equipped with a static mixer (302). Dispensing the reactive components, to the wound, through the static mixer (302) causes a chemical reaction to start which then continues in the wound chamber under the drape (103). It has been found that expansion within the wound chamber against the closed wound bed and closed drape surprisingly allows the injected material to generate a foam without causing the overlying drape to lift away from the wound bed. As illustrated in FIG. 4 instead of the drape lifting away from the wound bed injected filler material which is surplus to requirements to fill the wound chamber (200) merely escapes through the aperture during the injection process. The excess material (400) can then simply be removed by clinical staff using scissors or a knife. During the injection phase, as illustrated in FIG. 3, the nozzle (303) of the syringe (301) can be used to urge the injected filler throughout the wound cavity. This is particularly advantageous to ensure that the filler abuts the wound edge regions and thus completely fills the wound cavity. Subsequent to injecting the filler the excess material is removed and once completely cured, the suction head (106) can be secured over the aperture (105) and negative pressure wound therapy can begin.



FIG. 5 illustrates an alternative embodiment of the present invention in which instead of the double-barrel syringe (301) used to inject a filler material a pressurized canister (500) is utilised to inject string-like filler material into a wound cavity. FIG. 5 also illustrates an optional wound contact layer (501) which, as noted above, might also be used with the previously referred-to embodiment.


In order to utilise the string-like filler material a wound bed is first covered by a wound contact layer (501) and then a drape (103) is secured over the wound site. The drape is secured to provide a leak-free seal around the wound bed. An aperture (103) is preformed in the drape (103) or is then generated in the drape by clinical staff. The pressurised canister (500) contains pre-stored material under pressure and this is released along a dispensing nozzle (502) when a user presses a cap (503) in the direction A shown in FIG. 5. The filler material stored in the canister (500) is then released along the nozzle (502) and injected into the wound chamber as a string. As this string cures a porous lattice structure is generated in the wound chamber. As with the previous embodiment the nozzle can be used to ensure the filler reaches all regions within the wound cavity.


Embodiments of the present invention provide the advantage that a filler can be formed suitable for the application of NPWT which conforms intimately with a wound bed or wound contact layer and is also prevented from falling out of a wound by a pre-arranged drape. This means that it is possible to dress wounds with a filler for NPWT on all parts of the body, either via a single person or with minimal assistance. This also avoids the need to place a patient in awkward position or helps keep such placement to a minimum.


An example of one embodiment of the present invention but not limited to maybe, the process comprising:

    • securing at least one drape element over a chosen site; and
    • subsequently injecting a liquid state wound dressing filler material through at least one opening in the drape, in which under the drape the liquid state wound dressing filler is reacting giving off gas and subsequently hardens to a solid/semi-solid porous wound filler under the drape.


Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

Claims
  • 1. A solventless system for forming a porous wound filler at a wound site, comprising: a drape comprising an opening and configured to be secured over a wound cavity to form a seal;a base component;a catalyst component;a releasing agent;a mixer configured to mix the base component, catalyst component, and releasing agent to form a liquid filler material, the mixer configured to deliver the liquid filler material to the wound cavity; andwherein the base component and the catalyst component of the liquid filler material are configured to react to form a wound filler comprising: a solid porous wound filling portion positioned under the drape; anda removable excess portion positioned outside the wound cavity, wherein the base component and the catalyst component of the liquid foam filler are further configured to react to expand outward to form a porous wound filler and apply an outward force against the wound cavity and the drape to direct the porous wound filler through the aperture to form the removable excess portion without causing the seal to lift away from the wound cavity.
  • 2. The solventless system of claim 1, wherein the base component comprises polydimethylsiloxane.
  • 3. The solventless system of claim 1, wherein the catalyst component comprises platinum.
  • 4. The solventless system of claim 1, wherein the releasing agent comprises hydrogen.
  • 5. The solventless system of claim 1, wherein the drape is gas permeable.
  • 6. The solventless system of claim 1, wherein the solid porous wound filling portion of the wound filler comprises biocompatible foam.
  • 7. The solventless system of claim 6, wherein the solid porous wound filling portion of the wound filler comprises silicon-based foam.
  • 8. The solventless system of claim 6, wherein the solid porous wound filling portion of the wound filler comprises polyurethane based foam.
  • 9. The solventless system of claim 1, wherein the solid porous wound filling portion of the wound filler contacts a surface of the wound.
  • 10. The solventless system of claim 1, wherein the solid porous wound filling portion of the wound filler substantially fills an entire volume of the wound cavity.
  • 11. The solventless system of claim 1, wherein the removable excess portion of the wound filler is semi-solid.
  • 12. The solventless system of claim 1, wherein the removable excess portion of the wound filler is configured to be removable with a cutting implement.
  • 13. A solventless system for forming a porous wound filler at a wound site, comprising: a drape comprising an opening and configured to be secured over a wound cavity to form a seal;an injector comprising a nozzle member and configured to inject a filler material through the opening in the drape via the nozzle member;a liquid filler material contained in the injector and configured to expand outward as the liquid filler material cures to form: a solid porous wound filling portion positioned under the drape;a removable excess portion positioned outside the wound cavity, wherein the liquid filler material is further configured to apply an outward force against the wound cavity and the drape as the liquid filler material cures to thereby direct the liquid filler material through the opening to form a removable excess portion positioned outside the wound cavity without causing the seal to lift away from the wound cavity, and;a suction port configured to be secured over the opening of the drape subsequent to injecting the filler material through the opening of the drape and further configured to fluidicly connect the injected filler material to a source of negative pressure.
  • 14. The apparatus of claim 13, further comprising a source of negative pressure.
  • 15. The apparatus of claim 14, wherein the source of negative pressure comprises a vacuum pump system.
  • 16. A solventless system for forming a porous wound filler at a wound site, comprising: a wound dressing comprising: a drape comprising an opening and configured to be secured over a wound cavity to form a seal;a liquid filler material configured to be injectable under the drape through the opening, the liquid filler material configured to cure into: a solid wound filling portion configured to substantially fill an entire volume of the wound cavity;an excess portion positioned outside the wound cavity, wherein the liquid filler material is further configured to apply an outward force against the wound cavity and the drape as the liquid filler material cures to thereby direct the liquid filler material through the opening to form a removable excess portion positioned outside the wound cavity without causing the seal to lift away from the wound cavity, and;a fluid communication port configured to be locatable over the opening in the drape and to fluidly connect the cured filler material with a source of negative pressure.
  • 17. The apparatus of claim 16, further comprising a source of negative pressure.
  • 18. The apparatus of claim 17, wherein the source of negative pressure comprises a vacuum pump system.
  • 19. The apparatus of claim 16, the liquid filler material further configured to expand outward as the liquid filler material cures.
Priority Claims (1)
Number Date Country Kind
1011173.0 Jul 2010 GB national
US Referenced Citations (283)
Number Name Date Kind
3274155 Saunders et al. Sep 1966 A
3646155 Scott et al. Feb 1972 A
3783870 Schachet Jan 1974 A
3808178 Gaylord Apr 1974 A
3809086 Schachet et al. May 1974 A
3809087 Lewis, Jr. May 1974 A
3928629 Chandra et al. Dec 1975 A
4073294 Stanley et al. Feb 1978 A
4117551 Books et al. Sep 1978 A
4266545 Moss May 1981 A
4278089 Huck et al. Jul 1981 A
4392860 Huck et al. Jul 1983 A
4529553 Faltynek Jul 1985 A
4538920 Drake et al. Sep 1985 A
4569674 Phillips et al. Feb 1986 A
4578060 Huck et al. Mar 1986 A
4655754 Richmond et al. Apr 1987 A
4661093 Beck et al. Apr 1987 A
4713052 Beck et al. Dec 1987 A
4714739 Arkles Dec 1987 A
4753536 Spehar et al. Jun 1988 A
4767026 Keller Aug 1988 A
4771919 Ernst Sep 1988 A
4798583 Beck et al. Jan 1989 A
4826494 Richmond et al. May 1989 A
4872450 Austad Oct 1989 A
4923444 Daoud et al. May 1990 A
4936834 Beck et al. Jun 1990 A
4969880 Zamierowski Nov 1990 A
5010115 Grisoni Apr 1991 A
5033650 Colin et al. Jul 1991 A
5064653 Sessions et al. Nov 1991 A
5080493 McKown et al. Jan 1992 A
5089606 Cole et al. Feb 1992 A
5100395 Rosenberg Mar 1992 A
5141503 Sewell, Jr. Aug 1992 A
5145933 Grisoni et al. Sep 1992 A
5153231 Bouquet et al. Oct 1992 A
5249709 Duckworth et al. Oct 1993 A
5266326 Barry et al. Nov 1993 A
5333760 Simmen et al. Aug 1994 A
5348392 Bouquet et al. Sep 1994 A
5397848 Yang et al. Mar 1995 A
5456745 Rorefer et al. Oct 1995 A
5549584 Gross Aug 1996 A
5582596 Fukunaga et al. Dec 1996 A
5583114 Barrows et al. Dec 1996 A
5609271 Keller et al. Mar 1997 A
5612050 Rowe et al. Mar 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5660823 Chakrabarti et al. Aug 1997 A
5717030 Dunn et al. Feb 1998 A
5747064 Burnett et al. May 1998 A
5776193 Kwan et al. Jul 1998 A
5834007 Kubota Nov 1998 A
5840777 Eagles et al. Nov 1998 A
5874500 Rhee et al. Feb 1999 A
D406899 Cottle Mar 1999 S
RE36235 Keller et al. Jun 1999 E
5944703 Dixon et al. Aug 1999 A
5945115 Dunn et al. Aug 1999 A
5962010 Greff et al. Oct 1999 A
5998472 Berger et al. Dec 1999 A
6024731 Seddon et al. Feb 2000 A
6135116 Vogel et al. Oct 2000 A
D434150 Tumey et al. Nov 2000 S
6142982 Hunt et al. Nov 2000 A
6143352 Clark et al. Nov 2000 A
6165201 Sawhney et al. Dec 2000 A
6168788 Wortham Jan 2001 B1
D439341 Tumey et al. Mar 2001 S
6214332 Askill et al. Apr 2001 B1
6252129 Coffee Jun 2001 B1
6261276 Reitsma Jul 2001 B1
6345623 Heaton et al. Feb 2002 B1
6391294 Dettmar et al. May 2002 B1
6398761 Bills et al. Jun 2002 B1
6447802 Sessions et al. Sep 2002 B2
6458109 Henley et al. Oct 2002 B1
6486285 Fujita Nov 2002 B2
6495127 Wallace et al. Dec 2002 B1
6509031 Miller et al. Jan 2003 B1
6521251 Askill et al. Feb 2003 B2
6527203 Hurray et al. Mar 2003 B2
6547467 Quintero Apr 2003 B2
6553998 Heaton et al. Apr 2003 B2
6564972 Sawhney et al. May 2003 B2
6569113 Wirt et al. May 2003 B2
6575940 Levinson et al. Jun 2003 B1
6596704 Court et al. Jul 2003 B1
6627216 Brandt et al. Sep 2003 B2
6629774 Guruendeman Oct 2003 B1
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6698622 Sawhney et al. Mar 2004 B2
6730299 Tayot et al. May 2004 B1
6732887 Bills May 2004 B2
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6790438 Constancis et al. Sep 2004 B1
6800074 Henley et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6820766 Keller et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6840462 Hurray et al. Jan 2005 B2
6855135 Lockwood et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6926695 Levinson et al. Aug 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Johnson Dec 2005 B2
6994702 Johnson Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7117869 Heaton et al. Oct 2006 B2
7129210 Lowinger et al. Oct 2006 B2
7132170 Parker Nov 2006 B2
7175336 Voellmicke et al. Feb 2007 B2
7279612 Heaton et al. Oct 2007 B1
7303757 Schankereli et al. Dec 2007 B2
7316330 Muller et al. Jan 2008 B2
7387432 Lu et al. Jun 2008 B2
7396507 Grunwald et al. Jul 2008 B2
7524315 Blott et al. Apr 2009 B2
7543843 Keshavaraj et al. Jun 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7611500 Lina et al. Nov 2009 B1
7635343 McIntosh et al. Dec 2009 B2
7674837 Gaserod et al. Mar 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7708940 Grunwald et al. May 2010 B2
7717313 Criscuolo et al. May 2010 B2
7722582 Lina et al. May 2010 B2
7758554 Lina et al. Jul 2010 B2
7776028 Miller et al. Aug 2010 B2
7862831 Wang et al. Jan 2011 B2
7882983 Reidt et al. Feb 2011 B2
7910135 St. John et al. Mar 2011 B2
7922743 Heinrich et al. Apr 2011 B2
7954672 Keller Jun 2011 B2
8007164 Tatsunosuke et al. Aug 2011 B2
8025650 Anderson et al. Sep 2011 B2
8074843 Keller Dec 2011 B2
8096979 Lina et al. Jan 2012 B2
8100887 Weston et al. Jan 2012 B2
8119160 Looney et al. Feb 2012 B2
8162909 Blott et al. Apr 2012 B2
8225981 Criscuolo et al. Jul 2012 B2
8226942 Charier et al. Jul 2012 B2
8267918 Johnson et al. Sep 2012 B2
8273368 Ambrosio et al. Sep 2012 B2
8282611 Weston Oct 2012 B2
8286832 Keller Oct 2012 B2
8303552 Weston Nov 2012 B2
8410189 Carnahan et al. Apr 2013 B2
8481801 Addison et al. Jul 2013 B2
8540699 Miller et al. Sep 2013 B2
8613734 Lina et al. Dec 2013 B2
8708998 Weston et al. Apr 2014 B2
8753670 Delmotte Jun 2014 B2
8771253 Johnson et al. Jul 2014 B2
8795635 Tamarkin et al. Aug 2014 B2
8795713 Makower et al. Aug 2014 B2
8801685 Armstrong et al. Aug 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8894620 Swain Nov 2014 B2
8968773 Thomas et al. Mar 2015 B2
8998866 Hicks Apr 2015 B2
9028872 Gaserod et al. May 2015 B2
20010004082 Keller et al. Jun 2001 A1
20010043913 Spaans et al. Nov 2001 A1
20020010299 Guyuron et al. Jan 2002 A1
20020038826 Hurray et al. Apr 2002 A1
20020122771 Holland et al. Sep 2002 A1
20020143286 Tumey Oct 2002 A1
20020145007 Sawhney et al. Oct 2002 A1
20020146662 Radl et al. Oct 2002 A1
20020183702 Henley et al. Dec 2002 A1
20020187182 Kramer et al. Dec 2002 A1
20020198490 Wirt et al. Dec 2002 A1
20030040478 Drucker et al. Feb 2003 A1
20030069535 Shalaby Apr 2003 A1
20030069563 Johnson Apr 2003 A1
20030093041 Risk, Jr. et al. May 2003 A1
20030143189 Askill et al. Jul 2003 A1
20030183653 Bills Oct 2003 A1
20030212357 Pace Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040033466 Shellard et al. Feb 2004 A1
20040037897 Benjamin et al. Feb 2004 A1
20040049187 Burnett et al. Mar 2004 A1
20040073151 Weston Apr 2004 A1
20040073152 Karason et al. Apr 2004 A1
20040121438 Quirk Jun 2004 A1
20040167617 Voellmicke et al. Aug 2004 A1
20040171998 Marasco, Jr. Sep 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20050010153 Lockwood et al. Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050085795 Lockwood et al. Apr 2005 A1
20050100692 Parker May 2005 A1
20050148913 Weston Jul 2005 A1
20050163904 Walker et al. Jul 2005 A1
20050203452 Weston et al. Sep 2005 A1
20050222527 Miller et al. Oct 2005 A1
20050222528 Weston Oct 2005 A1
20050230422 Muller et al. Oct 2005 A1
20050261642 Weston Nov 2005 A1
20060015087 Risk, Jr. et al. Jan 2006 A1
20060079599 Arthur Apr 2006 A1
20060100586 Karpowicz et al. May 2006 A1
20060173253 Ganapathy et al. Aug 2006 A1
20060173514 Biel et al. Aug 2006 A1
20060217016 Lin et al. Sep 2006 A1
20060253082 Mcintosh et al. Nov 2006 A1
20060273109 Keller Dec 2006 A1
20070004896 Ito et al. Jan 2007 A1
20070009580 DiCosmo et al. Jan 2007 A1
20070141101 Nugent et al. Jun 2007 A1
20070147947 Stenton et al. Jun 2007 A1
20070164047 Reidt et al. Jul 2007 A1
20070185463 Mulligan Aug 2007 A1
20070186404 Drew et al. Aug 2007 A1
20070203062 Ellis-Behnke et al. Aug 2007 A1
20070219513 Lina et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070237811 Scherr Oct 2007 A1
20070248642 Dornish et al. Oct 2007 A1
20080004549 Anderson et al. Jan 2008 A1
20080060550 MacDonald et al. Mar 2008 A1
20080089173 Lu et al. Apr 2008 A1
20080206155 Tamarkin et al. Aug 2008 A1
20080208163 Wilkie Aug 2008 A1
20080232187 Tatsunosuke et al. Sep 2008 A1
20080254103 Harris et al. Oct 2008 A1
20080279807 Belcheva et al. Nov 2008 A1
20080287880 Keller Nov 2008 A1
20080314929 Keller Dec 2008 A1
20090020561 Keller Jan 2009 A1
20090022779 Kelly et al. Jan 2009 A1
20090030086 Eady et al. Jan 2009 A1
20090093550 Rolfes et al. Apr 2009 A1
20090098073 MacDonald et al. Apr 2009 A1
20090134186 Keller May 2009 A1
20090157017 Ambrosio Jun 2009 A1
20090196844 Choi et al. Aug 2009 A1
20090275872 Addison et al. Nov 2009 A1
20090287181 Kagan Nov 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20100022972 Lina et al. Jan 2010 A1
20100030132 Niezgoda et al. Feb 2010 A1
20100036305 Green Feb 2010 A1
20100036334 Heagle et al. Feb 2010 A1
20100069850 Fabo Mar 2010 A1
20100125259 Olson May 2010 A1
20100135915 Greener Jun 2010 A1
20100137775 Hu et al. Jun 2010 A1
20100230467 Crisuolo et al. Sep 2010 A1
20100268177 Hall et al. Oct 2010 A1
20110021431 Jones et al. Jan 2011 A1
20110028919 Johnnison et al. Feb 2011 A1
20110033503 Sinko et al. Feb 2011 A1
20110036889 Heinrich et al. Feb 2011 A1
20110086077 McCrea et al. Apr 2011 A1
20110118683 Weston May 2011 A1
20110147432 Heinrich et al. Jun 2011 A1
20110147435 Heinrich et al. Jun 2011 A1
20110251567 Blott et al. Oct 2011 A1
20120083755 Lina et al. Apr 2012 A1
20120123356 Greener May 2012 A1
20130023841 Johnson et al. Jan 2013 A1
20130096519 Blott et al. Apr 2013 A1
20130274688 Weston Oct 2013 A1
20130310780 Phillips Nov 2013 A1
20130310781 Phillips Nov 2013 A1
20140012214 Miller et al. Jan 2014 A1
20140228792 Weston et al. Aug 2014 A1
Foreign Referenced Citations (271)
Number Date Country
3 838 587 May 1990 DE
0 251 810 Jan 1988 EP
0 355 536 Feb 1990 EP
0 358 302 Mar 1990 EP
0 521 434 Jul 1993 EP
0 325 771 Sep 1993 EP
0 425 164 Sep 1994 EP
0 648 122 Apr 1995 EP
0 690 736 Jan 1996 EP
0 578 999 May 1996 EP
0 724 888 Aug 1996 EP
0 549 781 Sep 1996 EP
0 754 064 Jan 1997 EP
0 762 860 Mar 1997 EP
0 772 464 May 1997 EP
0 793 019 Sep 1997 EP
0 537 559 Jan 1998 EP
0 620 720 Mar 1998 EP
0 856 318 Aug 1998 EP
0 858 810 Aug 1998 EP
0 651 983 Sep 1998 EP
0 876 165 Nov 1998 EP
0 888 141 Jan 1999 EP
0 912 251 May 1999 EP
0 923 905 Jun 1999 EP
0 617 152 Aug 1999 EP
1 007 015 Jun 2000 EP
1 013 290 Jun 2000 EP
1 021 180 Jul 2000 EP
1 029 585 Aug 2000 EP
1 030 657 Aug 2000 EP
0 688 189 Sep 2000 EP
1 085 925 Mar 2001 EP
1 088 569 Apr 2001 EP
1 105 110 Jun 2001 EP
1 105 171 Jun 2001 EP
1 105 180 Jun 2001 EP
1 107 813 Jun 2001 EP
1 114 933 Jul 2001 EP
1 138 336 Oct 2001 EP
1 156 839 Nov 2001 EP
0 921 775 Dec 2001 EP
0 564 502 Jan 2002 EP
1 218 437 Jul 2002 EP
1 306 123 Feb 2003 EP
1 440 737 Jul 2004 EP
1 139 951 Oct 2004 EP
1 632 252 Mar 2006 EP
1 633 830 Mar 2006 EP
1 758 637 Mar 2007 EP
1 798 835 Jun 2007 EP
1 978 046 Oct 2008 EP
1 988 125 Nov 2008 EP
1 993 512 Nov 2008 EP
2 111 804 Oct 2009 EP
1 637 088 Jan 2010 EP
2 255 837 Dec 2010 EP
2 263 627 Dec 2010 EP
1 374 914 Mar 2011 EP
2 335 747 Jun 2011 EP
1 169 071 Feb 2012 EP
2 127 690 Jun 2012 EP
1 177 781 Aug 2012 EP
2 643 412 Oct 2013 EP
2288734 Nov 1995 GB
2306580 May 1997 GB
2307180 May 1997 GB
2329127 Mar 1999 GB
2305610 Jul 1999 GB
2422545 Aug 2006 GB
2423019 Aug 2006 GB
2424581 Oct 2006 GB
2424582 Oct 2006 GB
2435419 Feb 2007 GB
2435422 Aug 2007 GB
2002-507435 Mar 2002 JP
2002-320625 Nov 2002 JP
2003-521962 Jul 2003 JP
2005 261376 Sep 2005 JP
2005-334188 Dec 2005 JP
WO 1992009301 Jun 1992 WO
WO 199209651 Jun 1992 WO
WO 199210983 Jul 1992 WO
WO 199306802 Apr 1993 WO
WO 199309176 May 1993 WO
WO 1994020133 Sep 1994 WO
WO 199421207 Sep 1994 WO
WO 199503838 Feb 1995 WO
WO 199504511 Feb 1995 WO
WO 199600760 Jan 1996 WO
WO 199601731 Jan 1996 WO
WO 199640174 Dec 1996 WO
WO 199703717 Feb 1997 WO
WO 199711658 Apr 1997 WO
WO 199713520 Apr 1997 WO
WO 199714384 Apr 1997 WO
WO 199733922 Sep 1997 WO
WO 199738732 Oct 1997 WO
WO 199742986 Nov 1997 WO
WO 199743991 Nov 1997 WO
WO 199803267 Jan 1998 WO
WO 199806444 Feb 1998 WO
WO 199813000 Apr 1998 WO
WO 199915121 Apr 1999 WO
WO 199917698 Apr 1999 WO
WO 199919013 Apr 1999 WO
WO 199923010 May 1999 WO
WO 199930629 Jun 1999 WO
WO 199939671 Aug 1999 WO
WO 1999047097 Sep 1999 WO
WO 199948621 Sep 1999 WO
WO 199964081 Dec 1999 WO
WO 199965536 Dec 1999 WO
WO 200000016 Jan 2000 WO
WO 200009199 Feb 2000 WO
WO 200017968 Mar 2000 WO
WO 2000038752 Jul 2000 WO
WO 200040190 Jul 2000 WO
WO 200061206 Oct 2000 WO
WO 200062827 Oct 2000 WO
WO 2000064396 Nov 2000 WO
WO 2000074738 Dec 2000 WO
WO 2001005443 Jan 2001 WO
WO 200110363 Feb 2001 WO
WO 200135882 May 2001 WO
WO 200137773 May 2001 WO
WO 2001041779 Jun 2001 WO
WO 200149233 Jul 2001 WO
WO 2001062312 Aug 2001 WO
WO 2001066017 Sep 2001 WO
WO 2001072251 Oct 2001 WO
WO 2002000268 Jan 2002 WO
WO 200202079 Jan 2002 WO
WO 200205737 Jan 2002 WO
WO 200209765 Feb 2002 WO
WO 200217840 Mar 2002 WO
WO 200220026 Mar 2002 WO
WO 200224132 Mar 2002 WO
WO 2002034304 May 2002 WO
WO 200238096 May 2002 WO
WO 2002064182 Aug 2002 WO
WO 2002070040 Sep 2002 WO
WO 2002094256 Nov 2002 WO
WO 2002102864 Dec 2002 WO
WO 2003005943 Jan 2003 WO
WO 2003020358 Mar 2003 WO
WO 2003022333 Mar 2003 WO
WO 2003041686 May 2003 WO
WO 2003041786 May 2003 WO
WO 2003063923 Aug 2003 WO
WO 2003065877 Aug 2003 WO
WO 2003071991 Sep 2003 WO
WO 2003072748 Sep 2003 WO
WO 2004012678 Feb 2004 WO
WO 2004016313 Feb 2004 WO
WO 2004032977 Apr 2004 WO
WO 2004037334 May 2004 WO
WO 2004045498 Jun 2004 WO
WO 2004054632 Jul 2004 WO
WO 2004060148 Jul 2004 WO
WO 2004091370 Oct 2004 WO
WO 2004098474 Nov 2004 WO
WO 2004108175 Dec 2004 WO
WO 2005009225 Feb 2005 WO
WO 2005009488 Feb 2005 WO
WO 2005017000 Feb 2005 WO
WO 2005018695 Mar 2005 WO
WO 2005019343 Mar 2005 WO
WO 2005021042 Mar 2005 WO
WO 2005025447 Mar 2005 WO
WO 2005034875 Apr 2005 WO
WO 2005046760 May 2005 WO
WO 2005079877 Sep 2005 WO
WO 2005082435 Sep 2005 WO
WO 2005118011 Dec 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006002528 Jan 2006 WO
WO 2006005939 Jan 2006 WO
WO 2006013084 Feb 2006 WO
WO 2006014534 Feb 2006 WO
WO 2006028244 Mar 2006 WO
WO 2006030054 Mar 2006 WO
WO 2006034128 Mar 2006 WO
WO 2006034166 Mar 2006 WO
WO 2006042169 Apr 2006 WO
WO 2006046060 May 2006 WO
WO 2006079822 Aug 2006 WO
WO 2006081403 Aug 2006 WO
WO 2006107387 Oct 2006 WO
WO 2006114637 Nov 2006 WO
WO 2006116524 Nov 2006 WO
WO 2006116992 Nov 2006 WO
WO 2006131747 Dec 2006 WO
WO 2006135506 Dec 2006 WO
WO 2006135934 Dec 2006 WO
WO 2007030601 Mar 2007 WO
WO 2007031757 Mar 2007 WO
WO 2007031762 Mar 2007 WO
WO 2007089103 Aug 2007 WO
WO 2007092397 Aug 2007 WO
WO 2007092405 Aug 2007 WO
WO 2007095180 Aug 2007 WO
WO 2007103208 Sep 2007 WO
WO 2007106590 Sep 2007 WO
WO 2007106594 Sep 2007 WO
WO 2007116347 Oct 2007 WO
WO 2007123451 Nov 2007 WO
WO 2007123598 Nov 2007 WO
WO 2007124198 Nov 2007 WO
WO 2007133618 Nov 2007 WO
WO 2007139812 Dec 2007 WO
WO 2007143060 Dec 2007 WO
WO 2008032232 Mar 2008 WO
WO 2008036162 Mar 2008 WO
WO 2008040020 Apr 2008 WO
WO 2008040681 Apr 2008 WO
WO 2008041926 Apr 2008 WO
WO 2008043067 Apr 2008 WO
WO 2008057600 May 2008 WO
WO 2008060475 May 2008 WO
WO 2008070270 Jun 2008 WO
WO 2008076407 Jun 2008 WO
WO 2008082444 Jul 2008 WO
WO 2008086397 Jul 2008 WO
WO 2008091521 Jul 2008 WO
WO 2008100437 Aug 2008 WO
WO 2008103891 Aug 2008 WO
WO 2008104609 Sep 2008 WO
WO 2008129318 Oct 2008 WO
WO 2008133918 Nov 2008 WO
WO 2008134544 Nov 2008 WO
WO 2008134774 Nov 2008 WO
WO 2008135997 Nov 2008 WO
WO 2009007785 Jan 2009 WO
WO 2009011856 Jan 2009 WO
WO 2009038783 Mar 2009 WO
WO 2009042514 Apr 2009 WO
WO 2009047524 Apr 2009 WO
WO 2009047655 Apr 2009 WO
WO 2009052193 Apr 2009 WO
WO 2009060327 May 2009 WO
WO 2009062327 May 2009 WO
WO 2009073401 Jun 2009 WO
WO 2009077722 Jun 2009 WO
WO 2009083544 Jul 2009 WO
WO 2009086580 Jul 2009 WO
WO 2009088726 Jul 2009 WO
WO 2009088925 Jul 2009 WO
WO 2009098595 Aug 2009 WO
WO 2009102021 Aug 2009 WO
WO 2009102952 Aug 2009 WO
WO 2009103031 Aug 2009 WO
WO 2009120432 Oct 2009 WO
WO 2009122989 Oct 2009 WO
WO 2009123720 Oct 2009 WO
WO 2009124100 Oct 2009 WO
WO 2009124407 Oct 2009 WO
WO 2009126102 Oct 2009 WO
WO 2009140376 Nov 2009 WO
WO 2009156709 Dec 2009 WO
WO 2009158131 Dec 2009 WO
WO 2010006182 Jan 2010 WO
WO 2010019997 Jan 2010 WO
WO 2010059730 May 2010 WO
WO 2010068502 Jun 2010 WO
WO 2011072840 Jun 2011 WO
WO 2012001371 Jan 2012 WO
WO 2012009370 Jan 2012 WO
WO 2012069793 May 2012 WO
WO 2012069794 May 2012 WO
WO 2012074512 Jun 2012 WO
Non-Patent Literature Citations (13)
Entry
US 6,216,701, 04/2001, Heaton et al. (withdrawn)
U.S. Appl. No. 14/635,846, filed Mar. 2, 2015, Hicks et al.
International Preliminary Report on Patentability, re PCT Application No. PCT/GB2011/000998, dated Jan. 17, 2013.
Letter from Dr. Tanja Bendele, LL.M. at RUHR re EP 2643412 dated May 21, 2014 in 9 pages.
Meissner, J., “X-ray Sterilisation,” dated Mar. 1, 2008, in 3 pages. Retrieved from http://www.emdt.co.uk/article/x-ray-sterilisation.
Dethier et al., “X-ray Sterilisation,” The Technology of the Future, dated Feb. 1, 2010, in 3 pages. Retrieved from http://www.emdt.co.uk/article/x-ray-sterilisation-technology-future.
International Search Report for PCT Application No. PCT/GB2011/000998, dated Nov. 21, 2011.
Jahns et al., Poster “Problemwundversorgung mit einem neuen anschmiegsamen Silikonschaumverband mit Anwendung der Vakuumtechnik,” 2nd Congress of German Wound Treatment Society 1998.
Khan, et al., “Influence of Chitosan Molecular Weight on its Physical Properties”, EIMJM (2003); 2(1); pp. 1-8.
Sogias, et al., “Exploring the Factors Affecting the Solubility of Chitosan in Water”, Macromol. Chem. Phys. (2010); 211; pp. 426-433.
Wooding-Scott, Margaret, et al., “No Wound is Too Big for Resourceful Nurses,” RN Dec. 1988, pp. 22-25 USA.
Meissner, J., X-ray Sterilisation dated Mar. 1, 2008. Retrieved from http://www.emdt.com.uk/article/x-ray-sterilisation.
Dethier et al., X-ray Sterilisation. The Technology of the Future dated Feb. 1, 2010. Retrieved from http://www.emdt.co.uk/article/x-ray-sterilisation-technology-future.
Related Publications (1)
Number Date Country
20150335493 A1 Nov 2015 US
Continuations (2)
Number Date Country
Parent 14635846 Mar 2015 US
Child 14728950 US
Parent 13806722 US
Child 14635846 US